About Epocal
Epocal is a Healthcare company based in Ottawa (Canada) founded in 2001, and was acquired by Siemens in July 2017. Biochips and solid-state diagnostic devices for blood testing are developed. Epocal has raised $40.51 million across 6 funding rounds from investors including Siemens, Highland Capital and Genesys Capital. The company was acqui-hired. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Blood Analyzer.
Company details
Epocal researches and develops biochips and solid-state diagnostic devices. Epocal is implementing an entire blood diagnostic system in FlexCard technology, a card format similar to the smart card used in conventional check and telephone cards. Epocal manufactures cards at ultra low cost, leveraging already existing high volume low cost production technologies for smart cards. The proprietary FlexCard technology, comprising biosensors and integral fluidics on flex circuit modules in a credit card-sized housing. The companys new enterprise point-of-care blood diagnostic system, the Epoc comprising diagnostic test cards and wireless card readers is intended to be used in all low volume, distributed testing applications, where high sensitivity and lab quality accuracy is required: in hospitals at the bedside, in physicians offices and in patients homes.
- Headquarters Ottawa, Canada
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website epocal.com
- Social LinkedIn
- Acquired by Siemens (Jul 2017)
Funding Insights of Epocal
Epocal has successfully raised a total of $40.51M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $31 million completed in April 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40.51M
- Total Rounds 6
- Last Round Series C — $31M
- First Round $2.07M
(Jun 2001)
- Investors Count 3
All 6 funding rounds of Epocal with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2007 | $31M | Series C | – | – | |
| Jan 2006 | $2.5M | Debt – Venture | – | – | |
| Apr 2005 | $810,636 | Grant | – | – | – |
| Apr 2005 | $5.35M | Series B | – | – | – |
| Jun 2003 | $2.09M | Series A | – | – | |
| Jun 2001 | $2.07M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Epocal
Epocal has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Siemens, Highland Capital and Genesys Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life sciences companies are supported through venture capital investments. | genesyscapital.com | Toronto, Canada | ||
Tech & Life-Sciences focused Growth stage Venture Debt Firm investing in North America | mmvf.com | Toronto, Canada | ||
Investment management services are offered by Highland Capital. | highlandcapital.com | |||
Industrial software is developed for automation, electrification, and digitalization solutions. | 1847 | siemens.com | United States |
Investor details for Epocal
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Epocal
4 dated milestones of Epocal across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Epocal is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Series C, of $31.0M.
- Exit Acquired by Siemens.
Web traffic of Epocal
Websites that share an audience with Epocal (epocal.com).
Websites whose visitors overlap most with Epocal. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
oxoid.ca | oxoid.ca | 100% | – | ||
| sussex-research.com | 100% | 2.7K | #6,616,896 | View details | |
biomation.com | biomation.com | 100% | – | ||
| aegera.com | 100% | View details | |||
| informationmediary.com | 100% | 2.6K | #6,664,316 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Epocal
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Epocal
Epocal was founded in 2001.
Epocal is headquartered in Ottawa, Canada. It is registered at Ottawa, Ontario, Canada.
Epocal is a funded company, having raised a total of $40.51M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2.07M, raised on Jun 2001.
Epocal researches and develops biochips and solid-state diagnostic devices. Epocal is implementing an entire blood diagnostic system in FlexCard technology, a card format similar to the smart card used in conventional check and telephone cards. Epocal manufactures cards at ultra low cost, leveraging already existing high volume low cost production technologies for smart cards. The proprietary FlexCard technology, comprising biosensors and integral fluidics on flex circuit modules in a credit card-sized housing. The companys new enterprise point-of-care blood diagnostic system, the Epoc comprising diagnostic test cards and wireless card readers is intended to be used in all low volume, distributed testing applications, where high sensitivity and lab quality accuracy is required: in hospitals at the bedside, in physicians offices and in patients homes.
Epocal has 4 investors. Key investors include Siemens, Highland Capital, Genesys Capital, and MMV Financial.
Yes. Epocal was acquired by Siemens in July 2017.